Clinical trials: Treatment Resistant Depressive Disorder
Depressive Disorder, Treatment-Resistant
Accelerated Bilateral Sequential Theta Burst Stimulation in Older Adults With Treatment-resistant Depression
The CogniTReaD study is a pilot clinical trial that will compare the effects of active accelerated bilateral sequential theta burst stimulation (absTBS) and sham or inactive treatment.
- Trial name
- CogniTReaD (NCT06323486)
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Ontario Shores Centre for Mental Health Sciences
Treatment Resistant Depression, Refractory Depression
Ketamine for Older Adults Pilot
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine in older adults with Treatment-Resistant Depression (TRD).
- Conditions
- Treatment Resistant Depression, Refractory Depression, Therapy-Resistant Depression, Late Life Depression
- Trial name
- NCT04504175
- Testing
- Ketamine
- Where
- 5 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression
Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI
Healthy controls (HC) will be studied once to provide data needed to validate the virtual neuro-navigation system. All subjects will undergo a single MRI session and will then participate in an on-line neuro-navigation session in…
- Trial name
- NCT05598931
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Soterix Medical
Healthy
A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.
- Trial name
- NCT01546051
- Testing
- BCI-838, BCI-1038, BCI-1206 & BCI-1283
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Depression
A Study of Infliximab for Treatment Resistant Major Depression
Major depression is increasingly recognized to be a chronic and highly recurrent condition, which results in significantly increased health problems.
- Trial name
- Infliximab (NCT00463580)
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Treatment Resistant Major Depressive Disorder
This is a Study to Determine the Antidepressant Effects of AZD6765
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
- Trial name
- NCT00986479
- Testing
- AZD6765
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Depression and Quality of Life, Treatment Resistant Depression (TRD)
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings.
- Conditions
- Depression and Quality of Life, Treatment Resistant Depression (TRD), Anhedonia, Apathy
- Trial name
- ESKPSY (NCT07146503)
- Testing
- Esketamine (Intranasal Spray)
- Where
- 5 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Riccardo Guglielmo
Depression
Pulsed Electro Magnetic Fields (PEMF) Treatment in Patients With Treatment-Resistant Major Depression in Ongoing Pharmacological Treatment of Depression
About 30% of patients with major depression are treatment resistant to pharmacological treatment. In the search for new methods to treat depression a great interest has been put into the use of electromagnetic fields.
- Trial name
- NCT00287703
- Testing
- Pulsating Electro-Magnetic Fields
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Hillerod Hospital, Denmark
Bipolar II Depression
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder
This study is a 12-week (in addition to up to 30 days of screening) randomized, double-blind, placebo-controlled, parallel-group trial.
- Trial name
- PAT-BD-01 (NCT06943573)
- Testing
- psilocybin (25 mg), psilocybin 1mg micro-dose
- Where
- 3 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Lakshmi N Yatham
Multiple Sclerosis, Major Depressive Disorder
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS.
- Conditions
- Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06329414
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Depressive Disorder
Cerebral Neuroinflammation During Major Depressive Episode
the investigators make the following assumptions: 1) neuroinflammation in MDD can be measured by the [18 F ] DPA- 714 ; 2) it is accompanied by anatomical and functional changes in the frontal subcortical loops, strongly involved…
- Trial name
- InflaDep (NCT03314155)
- Testing
- Cerebral neuroinflammation evaluation
- Where
- 4 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Treatment Resistant Depression, Bipolar Depression
A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders
This study aims to openly test the long-term safety, tolerability and effectiveness of repeated administration of IV, nasal spray and oral ketamine for treatment-resistant mood disorders.
- Conditions
- Treatment Resistant Depression, Bipolar Depression, Ketamine, Major Depressive Disorder
- Trial name
- GDKet (NCT04226963)
- Testing
- Ketamine
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Medical University of Gdansk
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression
The goal of this study is to collect feasibility data on combining structured exercise aimed to improve physical fitness, and intermittent TBS (iTBS) in treating individuals diagnosed with difficult-to-treat depression who are…
- Trial name
- NCT06773949
- Testing
- Theta burst stimulation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Treatment Resistant Depression
Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study
This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.
- Trial name
- NCT03680781
- Testing
- Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC, Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Treatment Resistant Depression
Dorsomedial Prefrontal Cortex and the Antidepressant Efficacy of Theta Burst Stimulation in Depressed Patients
This study evaluates an association between different dosage and the antidepressant efficacy of theta burst stimulation in patients with treatment-resistant depression.
- Trial name
- NCT04037592
- Testing
- Active standardized iTBS-DMPFC, Active high-dosage iTBS-DMPFC
- Where
- Taiwan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Taipei Veterans General Hospital, Taiwan
MDD, Major Depressive Disorder
pBFS Guided rTMS Therapy Over Different Targets for Treatment-Resistant Depression
To explore the effectiveness and safety of rTMS intervention with different targets in the left prefrontal cortex defined using the pBFS method, in adult patients with moderate and severe depressive disorder.
- Conditions
- MDD, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT05976022
- Testing
- active rTMS
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Changping Laboratory
Treatment Resistant Depression
Cannabidiol for Treatment Resistant Depression
With this study, the investigators will address the following scientific aims: 1. Demonstrate the antidepressant effects of CBD in human adults with treatment refractory MDD as measured by standard rating scales. 2.
- Trial name
- CBD (NCT04732169)
- Testing
- Active study drug ( oral CBD)
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Depression, Depressive Disorder
Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling…
- Trial name
- PROSPECT (NCT00380042)
- Testing
- Cortical Stimulation
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northstar Neuroscience
Treatment Resistant Depression
Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment
This is a study of the chemistry of depression in people who are taking an antidepressant but it is not working well. The changes in brain chemicals that occur when an SSRI type antidepressant is supplemented with risperidone…
- Trial name
- NCT00178854
- Testing
- Risperidone
- Where
- United States
- Sponsor
- Vanderbilt University Medical Center
Major Depressive Disorder (MDD)
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium - Maintenance
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif XCS System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE-M (NCT07684794)
- Testing
- Motif XCS System
- Volunteers
- 10 people
- Sponsor
- Motif Neurotech, Inc.